Pfizer says Phase 3 LITFULO trials met key vitiligo endpoints; plans global regulatory filings
Pfizer said Phase 3 trials of LITFULO (ritlecitinib) met key endpoints in nonsegmental vitiligo across 2,174 patients, and it plans global regulatory filings.